KPV

Peptide

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) that exhibits potent anti-inflammatory and immunomodulatory properties. Preclinical studies have demonstrated significant efficacy in reducing intestinal inflammation in multiple models of inflammatory bowel disease, including DSS- and TNBS-induced colitis. Unlike full-length α-MSH, KPV's anti-inflammatory action is not primarily melanocortin receptor-mediated but is instead transported into cells via the PepT1 transporter. No human clinical trials have been conducted to date, limiting the evidence to animal and in vitro studies.

Quick Answer

What it is

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) that exhibits potent anti-inflammatory and immunomodulatory properties. Preclinical studies have demonstrated significant efficacy in reducing intestinal inflammation in multiple models of inflammatory bowel disease, including DSS- and TNBS-induced colitis.

Key findings

  • Grade C: GI Protection
  • Grade C: Immune Function
  • Grade C: Anti-Cancer Activity

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: KPV

Quick Facts: KPV

  • Best Evidence:Grade C
  • Conditions Studied:3
  • Research Outcomes:15
  • Key Effect:General Gut Health
A0
B0
C11
D4
3 conditions · 15 outcomes

Detailed Outcomes

|
C
GI Protection
10 preclinical studies support this finding. Primarily preclinical evidence.
moderateImproves
C
Immune Function
9 preclinical studies support this finding. Primarily preclinical evidence.
moderateImproves
C
Anti-Cancer Activity
6 preclinical studies support this finding. Primarily preclinical evidence.
smallImproves
C
Wound Healing
4 systematic reviews and preclinical studies support this finding. Evidence includes systematic reviews/meta-analyses. Primarily preclinical evidence.
smallImproves
C
Pulmonary Function
3 preclinical studies support this finding. Primarily preclinical evidence.
smallImproves
D
Antimicrobial Activity
2 preclinical studies support this finding. Primarily preclinical evidence.
smallImproves
D
Mortality
2 preclinical studies support this finding. Primarily preclinical evidence.
smallImproves
C
Intestinal Inflammation (Animal)
Rescued all animals from death in MC1R-deficient mice during DSS colitis
largeImproves
C
Colitis Severity (Animal)
Significant reduction in inflammatory infiltrates and MPO activity in DSS and TNBS colitis models
largeImproves
C
Pro-inflammatory Cytokine Reduction
Inhibition of TNF-α, IL-1β, and IL-6 secretion at nanomolar concentrations
moderateWorsens
D
Macrophage Activation Suppression
Inhibition of LPS-induced cytokine synthesis and CD86 expression
moderateWorsens
D
Anti-inflammatory (Topical)
Anti-inflammatory effect in crystal-induced peritonitis model
moderateImproves

Research Citations (48)

Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers.
(2026)
PMID: 41533788
Exploring the Role of Tripeptides in Wound Healing and Skin Regeneration: A Comprehensive Review.
(2025)
PMID: 41209547
Challenges in clinical nutrition research in Latin America: A narrative review.
(2025)
PMID: 41176232
A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment.
(2024)
PMID: 37859689
PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS.
(2024)
PMID: 39211778
Non-contrast-enhanced magnetic resonance urography for measuring split kidney function in pediatric patients with hydronephrosis: comparison with renal scintigraphy.
(2024)
PMID: 38041747
Learnings from the first AI-enabled skin cancer device for primary care authorized by FDA.
(2024)
PMID: 38879640
Growth Factors-Loaded Temperature-Sensitive Hydrogel as Biomimetic Mucus Attenuated Murine Ulcerative Colitis via Repairing the Mucosal Barriers.
(2024)
PMID: 38289234
The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials.
(2023)
PMID: 37508552
Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer.
(2023)
PMID: 37161053